PULMONARY EMBOLISM MORTALITY IN THE UNITED STATES (1999-2015): ANALYSIS OF THE MULTIPLE CAUSE OF DEATH DATA

ObjectiveTo report the incidence of prion disease in the United States.MethodsPrion disease decedents were retrospectively identified from the US national multiple cause-of-death data for 2003–2015 and matched with decedents in the National Prion Disease Pathology Surveillance Center (NPDPSC) database through comparison of demographic variables. NPDPSC decedents with neuropathologic or genetic test results positive for prion disease for whom no match was found in the multiple cause-of-death data were added as cases for incidence calculations; those with cause-of-death data indicating prion disease but with negative neuropathology results were removed. Age-specific and age-adjusted average annual incidence rates were then calculated.ResultsA total of 5,212 decedents were identified as having prion disease, for an age-adjusted average annual incidence of 1.2 cases per million population (range 1.0 per million [2004 and 2006] to 1.4 per million [2013]). The median age at death was 67 years. Ten decedents were <30 years of age (average annual incidence of 6.2 per billion); only 2 of these very young cases were sporadic forms of prion disease. Average annual incidence among those ≥65 years of age was 5.9 per million.ConclusionsPrion disease incidence can be estimated by augmenting mortality data with the results of neuropathologic and genetic testing. Cases <30 years of age were extremely rare, and most could be attributed to exogenous factors or the presence of a genetic mutation. Continued vigilance for prion diseases in all age groups remains prudent.

Download Full-text

Mortality in the US by education level

Annals of Actuarial Science ◽

10.1017/s1748499520000044 ◽

2020 ◽

Vol 14 (2) ◽

pp. 384-419

Author(s):

Cristian Redondo Lourés ◽

Andrew J. G. Cairns

Keyword(s):

United States ◽

Disease Control ◽

Cause Of Death ◽

The United States ◽

Mortality Rates ◽

Education Level ◽

The Us ◽

Control And Prevention ◽

Centers For Disease Control ◽

Death Data

AbstractDifferent mortality rates for different socio-economic groups within a population have been consistently reported throughout the years. In this study, we aim to exploit data from multiple public sources, including highly detailed cause-of-death data from the United States Centers for Disease Control and Prevention, to explore the mortality gap between the better and worse off in the US during the period 1989–2015, using education as a proxy.

Download Full-text

Faculty Opinions recommendation of Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: findings from the nationwide inpatient sample.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1161903.623526 ◽

2009 ◽

Author(s):

Imre Noth

Keyword(s):

United States ◽

Pulmonary Embolism ◽

Clinical Outcomes ◽

Resource Utilization ◽

Nationwide Inpatient Sample ◽

The United States ◽

Recent Trends

Download Full-text

Commercial Fishing as an Occupational Determinant of Opioid Overdoses and Deaths of Despair in Two Massachusetts Fishing Ports, 2000–2014

NEW SOLUTIONS A Journal of Environmental and Occupational Health Policy ◽

10.1177/10482911211023476 ◽

2021 ◽

pp. 104829112110234

Author(s):

Scott Fulmer ◽

Shruti Jain ◽

David Kriebel

Keyword(s):

United States ◽

Cause Of Death ◽

Death Certificate ◽

The United States ◽

Opioid Overdose ◽

Commercial Fishing ◽

Opioid Epidemic ◽

Death Certificate Data ◽

Deaths Of Despair

The opioid epidemic has had disproportionate effects across various sectors of the population, differentially impacting various occupations. Commercial fishing has among the highest rates of occupational fatalities in the United States. This study used death certificate data from two Massachusetts fishing ports to calculate proportionate mortality ratios of fatal opioid overdose as a cause of death in commercial fishing. Statistically significant proportionate mortality ratios revealed that commercial fishermen were greater than four times more likely to die from opioid poisoning than nonfishermen living in the same fishing ports. These important quantitative findings suggest opioid overdoses, and deaths to diseases of despair in general, deserve further study in prevention, particularly among those employed in commercial fishing.

Download Full-text

Prevalence of pulmonary embolism in 127 945 autopsies performed in cancer patients in the United States between 2003 and 2019

Journal of Thrombosis and Haemostasis ◽

10.1111/jth.15321 ◽

2021 ◽

Vol 19 (6) ◽

pp. 1591-1593

Author(s):

Luca Valerio ◽

Giacomo Turatti ◽

Frederikus A. Klok ◽

Stavros V. Konstantinides ◽

Nils Kucher ◽

...

Keyword(s):

United States ◽

Pulmonary Embolism ◽

Cancer Patients ◽

The United States

Download Full-text

Stroke Declines From Third to Fourth Leading Cause of Death in the United States

Stroke ◽

10.1161/strokeaha.111.621904 ◽

2011 ◽

Vol 42 (8) ◽

pp. 2351-2355 ◽

Cited By ~ 223

Author(s):

Amytis Towfighi ◽

Jeffrey L. Saver

Keyword(s):

United States ◽

Cause Of Death ◽

The United States

Download Full-text

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

BMC Cancer ◽

10.1186/s12885-021-07790-z ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Daniel C. Beachler ◽

Cynthia de Luise ◽

Aziza Jamal-Allial ◽

Ruihua Yin ◽

Devon H. Taylor ◽

...

Keyword(s):

Breast Cancer ◽

United States ◽

Pulmonary Embolism ◽

Cohort Study ◽

Real World ◽

The United States ◽

Elevated Risk ◽

Breast Cancer Patients ◽

Increased Risk ◽

Serious Infections

Abstract Background There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. Methods We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to September 2017 using the HealthCore Integrated Research Database (HIRD), a longitudinal claims database of commercial health plan members in the United States. The historical comparator cohort comprised patients initiating fulvestrant monotherapy from January 2011 to January 2015. Propensity score matching and Cox regression were used to estimate hazard ratios for various safety events. For acute liver injury (ALI), additional analyses and medical record validation were conducted. Results There were 2445 patients who initiated palbociclib including 566 new users of palbociclib-fulvestrant, and 2316 historical new users of fulvestrant monotherapy. Compared to these historical new users of fulvestrant monotherapy, new users of palbociclib-fulvestrant had a greater than 2-fold elevated risk for neutropenia, leukopenia, thrombocytopenia, stomatitis and mucositis, and ALI. Incidence of anemia and QT prolongation were more weakly associated, and incidences of serious infections and pulmonary embolism were similar between groups after propensity score matching. After adjustment for additional ALI risk factors, the elevated risk of ALI in new users of palbociclib-fulvestrant persisted (e.g. primary ALI algorithm hazard ratio (HR) = 3.0, 95% confidence interval (CI) = 1.1–8.4). Conclusions This real-world study found increased risks of several adverse events identified in clinical trials, including neutropenia, leukopenia, and thrombocytopenia, but no increased risk of serious infections or pulmonary embolism when comparing new users of palbociclib-fulvestrant to fulvestrant monotherapy. We observed an increased risk of ALI, extending clinical trial findings of significant imbalances in grade 3/4 elevations of alanine aminotransferase (ALT).

Download Full-text